Long-term virological outcome in children on antiretroviral therapy in the UK and Ireland

AIDS

Volumn 28, Issue 16, 2014, Pages 2395-2405

  Duong, Trinh ^a   Judd, Ali ^a   Collins, Intira Jeannie ^a   Doerholt, Katja ^b   Lyall, Hermione ^c   Foster, Caroline ^c   Butler, Karina ^d   Tookey, Pat ^e   Shingadia, Delane ^f   Menson, Esse ^g,bg   Dunn, David T ^a   Gibb, Di M ^a,f   Kenny, J ^bn   Bellenger, K ^bn   Childs, T ^bn   Dobson, D ^bn   Johnson, D ^bn   Tostevin, A ^bn   Walker, A S ^bn   Walker Nthenda, L ^bn   Tookey, P A ^e   Walsh , A ^d   Scott, S ^h   Vaughan, Y ^h   Welch, S ⁱ   Laycock, N ⁱ   Bernatoniene, J ^j   Finn, A ^j   Hutchison, L ^j   Sharpe, G ^k   Williams, A ^l,al   Lyall, E G H ^m,bf   Seery, P ^m,bf   Lewis, P ⁿ   Miles, K ⁿ   Subramaniam, B ^o   Hutchinson, L ^p,at,au,bh   Ward, P ^p   Sloper, K ^q   Gopal, G ^r   Doherty, C ^s   Hague, R ^s   Price, V ^s   Bundy, H ^f   Clapson, M ^f   Flynn, J ^f   Klein, N ^f   Novelli, V ^f   Ainsley Walker, P ^t   Tovey, P ^u   Gurtin, D ^v   Garside, J P ^w   Fall, A ^x   Porter, D ^y   Segal, S ^y   Ball, C ^z   Hawkins, S ^z   Chetcuti, P ^aa   Dowie, M ^aa   Bandi, S ^ab   McCabe, A ^ab   Eisenhut, M ^ac   Handforth, J ^ad   Roy, P K ^ae   Flood, T ^af   Pickering, A ^af   Liebeschuetz, S ^ag   Kavanagh, C ^ah   Murphy, C ^ai   Rowson, K ^ai   Tan, T ^ai   Daniels, J ^aj   Lees, Y ^aj   Kerr, E ^ak   Thompson, F ^ak   Le Provost, M ^al   Cliffe, L ^am   Smyth, A ^am   Stafford, S ^am   Freeman, A ^an   Reddy, T ^ao   Fidler, K ^ap   Christie, S ^aq   Gordon, A ^ar   Rogahn, D ^as   Harris, S ^at   Collinson, A ^au   Jones, L ^av   Offerman, B ^av   Van Someren, V ^aw   Benson, C ^ax   Riordan, A ^ax   Riddell, A ^ay   O'Connor, R ^az   Brown, N ^ba   Ibberson, L ^bb   Shackley, F ^bb   Faust, S N ^bc   Hancock, J ^bc   Doerholt, K ^bd   Donaghy, S ^bd   Prime, K ^bd   Sharland, M ^bd   Storey, S ^bd   Gorman, S ^be   Monrose, C ^bf   Tudor Williams, G ^bf   Walters, S ^bf   Cross, R ^bg   Broomhall, J ^bh   Scott, D ^bi   Stroobant, J ^bi   Bridgwood, A ^bj   McMaster, P ^bj   Evans, J ^bk   Gardiner, T ^bk   Jones, R ^bl   Gardiner, K ^bm   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^d OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^g GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^h BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

ⁱ BLACKPOOL VICTORIA HOSPITAL   (United Kingdom)

^j BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^k CALDERDALE ROYAL HOSPITAL   (United Kingdom)

^l CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

^m CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

ⁿ UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^o DERBYSHIRE CHILDREN S HOSPITAL   (United Kingdom)

^p DERRIFORD HOSPITAL   (United Kingdom)

^q EALING HOSPITAL   (United Kingdom)

^r EASTBOURNE DISTRICT GENERAL HOSPITAL   (United Kingdom)

^s ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^t Halliwell Children's Centre   (United Kingdom)

^u HARROGATE DISTRICT HOSPITAL   (United Kingdom)

^v HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^w HUDDERSFIELD ROYAL INFIRMARY   (United Kingdom)

^x JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^y JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^z KING S COLLEGE HOSPITAL   (United Kingdom)

^aa LEEDS GENERAL INFIRMARY   (United Kingdom)

^ab LEICESTER ROYAL INFIRMARY   (United Kingdom)

^ac LUTON AND DUNSTABLE HOSPITAL   (United Kingdom)

^ad MAYDAY UNIVERSITY HOSPITAL   (United Kingdom)

^ae MILTON KEYNES GENERAL HOSPITAL   (United Kingdom)

^af NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^ag NEWHAM UNIVERSITY HOSPITAL   (United Kingdom)

^ah NORFOLK AND NORWICH HOSPITAL   (United Kingdom)

^ai NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^aj NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

^ak NORTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^al NORTHWICK PARK HOSPITAL   (United Kingdom)

^am NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^an QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^ao RAIGMORE HOSPITAL   (United Kingdom)

^ap ALEXANDRA HOSPITAL   (United Kingdom)

^aq ROYAL BELFAST HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^ar ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

^as ROYAL ABERDEEN CHILDREN S HOSPITAL   (United Kingdom)

^at ROYAL CORNWALL HOSPITAL   (United Kingdom)

^au ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^av ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^aw ROYAL FREE HOSPITAL   (United Kingdom)

^ax ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

^ay ROYAL LONDON HOSPITAL   (United Kingdom)

^az ROYAL PRESTON HOSPITAL   (United Kingdom)

^ba SALISBURY DISTRICT HOSPITAL   (United Kingdom)

^bb SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^bc SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^bd ST GEORGE S HOSPITAL   (United Kingdom)

^be ST LUKE S HOSPITAL   (United Kingdom)

^bf ST MARY S HOSPITAL   (United Kingdom)

^bg ST THOMAS HOSPITAL   (United Kingdom)

^bh TORBAY HOSPITAL   (United Kingdom)

^bi UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

^bj UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^bk UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^bl Wexham Park General Surgery Hospital   (United Kingdom)

^bm WHIPPS CROSS UNIVERSITY HOSPITAL   (United Kingdom)

^bn Whipps Cross Hospital ^*

more..

Author keywords

Antiretroviral therapy; Children; HIV; UK Ireland; Virological outcome

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; DRUG EXPOSURE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRELAND; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; UNITED KINGDOM; VIROLOGICAL FAILURE; VIROLOGICAL OUTCOME; VIRUS LOAD; ADOLESCENT; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; INFANT; MULTICENTER STUDY; NEWBORN; PRESCHOOL CHILD; PROCEDURES; TREATMENT OUTCOME;

ADOLESCENT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; GREAT BRITAIN; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; IRELAND; MALE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84916204586     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000438     Document Type: Article

References (43)

1. Fitzgerald F, Penazzato M, Gibb D. Development of antiretroviral resistance in children with HIV in low- and middleincome countries. J Infect Dis 2013;207(Suppl 2):S85-92.
2. Sigaloff KC, Calis JC, Geelen SP, van Vugt M, de Wit TF. HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review. Lancet Infect Dis 2011;11:769-779.
3. Castro H, Judd A, Gibb DM, Butler K, Lodwick RK, van Sighem A, et al. Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet 2011;377:1580-1587.
4. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. June 2013. Geneva: World Health Organization. http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727-eng.pdf. [Accessed August 2013]
5. Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, Meyers T, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 2010;363:1510-1520.
6. Violari A, Lindsey JC, Hughes MD, Mujuru HA, Barlow-Mosha L, Kamthunzi P, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med 2012;366:2380-2389.
7. The PENPACT-1 Study Team. First-line antiretroviral therapy with a protease inhibitor versus nonnucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis 2011;11:273-283.
8. ARROW Trial Team. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet 2013;381:1391-1403.
9. Judd A. The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord. Early antiretroviral therapy in HIV-1-infected infants, 1996-2008: treatment response and duration of first-line regimens. AIDS 2011;25:2279-2287.
10. Pursuing Later Treatment Options (Plato II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Arch Intern Med 2010;170:410-419.
11. Davies MA, Moultrie H, Eley B, Rabie H, Van Cutsem G, Giddy J, et al. Virologic failure and second-line antiretroviral therapy in children in South Africa: the IeDEA Southern Africa collaboration. J Acquir Immune Defic Syndr 2011;56:270-278.
12. Lowenthal ED, Ellenberg JH, Machine E, Sagdeo A, Boiditswe S, Steenhoff AP, et al. Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children. JAMA 2013;309:1803-1809.
13. Sebunya R, Musiime V, Kitaka SB, Ndeezi G. Incidence and risk factors for first line anti retroviral treatment failure among Ugandan children attending an urban HIV clinic. AIDS Res Ther 2013;10:25.
14. Pillay P, Ford N, Shubber Z, Ferrand RA. Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis. PLoS One 2013;8:e68995.
15. Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011;154:445-456.
16. Ratsela A, Polis M, Dhlomo S, Emery S, Grandits G, Khabo P, et al. A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/muL in South Africa. J Infect Dis 2010;202:1529-1537.
17. Riddler SA, Haubrich R, Di Rienzo AG, Peeples L, Powderly WG, Klingman KL, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008;358:2095-2106.
18. Sierra-Madero J, Villasis-Keever A, Mendez P, Mosqueda-Gomez JL, Torres-Escobar I, Gutierrez-Escolano F, et al. Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200cell/mm3 in Mexico. J Acquir Immune Defic Syndr 2010;53:582-588.
19. Gibb DM, Duong T, Tookey PA, Sharland M, Tudor-Williams G, Novelli V, et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. Br Med J 2003;327:1019-1024.
20. Scherrer AU, Ledergerber B, von Wyl V, Boni J, Yerly S, Klimkait T, et al. Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. Clin Infect Dis 2011;53:1143-1152.
21. Cole TJ, Freeman JV, Preece MA. British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. Stat Med 1998;17:407-429.
22. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med 2009;10:591-613.
23. Arrive E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, Masquelier B, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 2007;36:1009-1021.
24. Royston P. Multiple imputation of missing data. Stata J 2004;4:227-241.
25. Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
26. Grigsby IF, Pham L, Mansky LM, Gopalakrishnan R, Mansky KC. Tenofovir-associated bone density loss. Ther Clin Risk Manag 2010;6:41-47.
27. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354:251-260.
28. Green H, Gibb DM, Walker AS, Pillay D, Butler K, Candeias F, et al. Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS 2007;21:947-955.
29. Post FA, Moyle GJ, Stellbrink HJ, Domingo P, Podzamczer D, Fisher M, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 2010;55:49-57.
30. Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 2011;204:1191-1201.
31. Tang MW, Kanki PJ, Shafer RW. A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy. Clin Infect Dis 2012;54:862-875.
32. World Health Organization. Global report: UNAIDS report on the global AIDS epidemic 2013. Geneva: World Health Organization. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS-Global-Report-2013-en.pdf. [Accessed January 2014]
33. Prendergast AJ, Penazzato M, Cotton M, Musoke P, Mulenga V, Abrams EJ, et al. Treatment of young children with HIV infection: using evidence to inform policymakers. PLoS Med 2012;9:e1001273.
34. Penazzato M, Giaquinto C. Role of nonnucleoside reverse transcriptase inhibitors in treating HIV-infected children. Drugs 2011;71:2131-2149.
35. Picat MQ, Lewis J, Musiime V, Prendergast A, Nathoo K, Kekitiinwa A, et al. Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study. PLoS Med 2013;10:e1001542.
36. Abrams EJ, Weedon J, Steketee RW, Lambert G, Bamji M, Brown T, et al. Association of human immunodeficiency virus (HIV) load early in life with disease progression among HIV-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group. J Infect Dis 1998;178:101-108.
37. Cotton MF, Violari A, Otwombe K, Panchia R, Dobbels E, Rabie H, et al. Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial. Lancet 2013;382:1555-1563.
38. Al-Dakkak I, Patel S, McCann E, Gadkari A, Prajapati G, Maiese EM. The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysis. AIDS Care 2013;25:400-414.
39. Fillekes Q, Mulenga V, Kabamba D, Kankasa C, Thomason MJ, Cook A, et al. Is nevirapine dose escalation appropriatein young, african, HIV-infected children? AIDS 2013;27:2111-2115.
40. Menson EN, Walker AS, Sharland M, Wells C, Tudor-Williams G, Riordan FA, et al. Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study. BMJ 2006;332:1183-1187.
41. Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, et al. Responsetoantiretroviraltherapy afterasingle, peripartum dose of nevirapine. N Engl J Med 2007;356:135-147.
42. Lodwick R, Costagliola D, Reiss P, Torti C, Teira R, Dorrucci M, et al. Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Arch Intern Med 2010;170:410-419.
43. Riordan A, Bugembe T. Update on antiretroviral therapy. Arch Dis Child 2009;94:70-74.